Dr. Chang was co-founder of Tanox, Inc., a biopharmaceutical company focused on addressing medical needs in the areas of allergy, asthma, inflammation, and diseases affecting the human immune system. Tanox’s initial public offering in 2000 was the second largest IPO for a biotechnology company, raising $244 million. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was acquired by Genentech in 2007 for $919 million.
Dr. Chang has served on the boards of directors of the Federal Reserve Bank in Houston, of BioHouston, of Project Hope, of Charles River Laboratories, and of the Board of Visitors of the University of Texas M.D. Anderson Cancer Center, among others.
Dr. Chang received her Ph.D. from Harvard Medical School.
